NASDAQ · Health care

iSpecimen Inc. (ISPC)

iSpecimen Inc. brought in $466.3K of revenue over the twelve months to June 30, 2026, down 92.1% from a year earlier. It posted a net loss of $11.4M. In fiscal 2025 capital spending exceeded operating cash flow by $4.2M. At June 30, 2026 it held $4.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Price

$1.26

+0.80% on the day · September 25, 2026

52-week range $1.18 to $53.20

Market cap

$3.2M

Revenue (last 12 months)

$466.3K

-92.1% year on year

Net margin

-2,449.0%

What iSpecimen Inc. does

iSpecimen Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker ISPC.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$1.9M	-$9M	-$10.5M	-$2.28	-$4.2M
2024	$9.3M	-$12.7M	-$12.5M	-$17.58	-$8.3M
2023	$9.9M	-$11.2M	-$11.1M	-$24.55	-$5.8M
2022	$10.4M	-$10.2M	-$10.2M	-$23.15	-$6M
2021	$11.1M	-$5.9M	-$9M	-$41.72	-$10.7M
2021	$8.2M	-$2.4M	-$4.7M	-$99.20	-$288.8K

Next report expected around October 21, 2026.

Estimated from its filing rhythm: about 68 days after its last report of August 14, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where ISPC ranks in Health care

Revenue$1.9M

#548 of 646 in Health care · Bottom 15%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What iSpecimen Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 14, 2026
Proxy statement DEF 14A
September 10, 2026
Stock exchange listing notice 8-K
September 4, 2026
Preliminary proxy statement PRE 14A
September 4, 2026
Material agreement 8-K
August 31, 2026
Executive or director change 8-K
August 14, 2026
Material agreement 8-K
August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 79% to $151.9K versus the same quarter last year; diluted EPS -$0.98 versus -$16.78.
August 11, 2026
Material agreement 8-K
August 7, 2026
Material agreement 8-K
August 7, 2026
Securities offering prospectus 424B4

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 19, 2025. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ISPC

What does iSpecimen Inc. do?

iSpecimen Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker ISPC.

Is iSpecimen Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $11.4M on revenue of $466.3K.

How much revenue does iSpecimen Inc. make?

Over the twelve months to June 30, 2026 iSpecimen Inc. reported revenue of $466.3K. That is 92.1% less than a year earlier.

When did iSpecimen Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from September 14, 2026.

Similar companies

Charles River Laboratories International, Inc.

MEDP

Medpace Holdings, Inc.

NOTVQ

Inotiv, Inc.

Compare ISPC with

Compare ISPC with any company

Follow ISPC

Get an email when iSpecimen Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ISPC: get an email when it files

Where the numbers come from

Financial figures are the values iSpecimen Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.